By vgreene, 18 June, 2019 KRAS1-3 prognostic; not indicated as routine stand-alone assay as a sole determinant of targeted tx; appropriate to include KRAS as part of larger testing panels performed either initially or when routine EFGR, ALK, BRAF, and ROS1 testing is negative2
By vgreene, 17 June, 2019 Tumor mutational burden (TMB) - may be helpful in selecting pts for immunotherapy but no consensus on how to measure it